



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Application of: ) Heteroaryl-substituted 1,3-dihydroindol-2-  
Wilfried Lubisch, et al. ) one derivatives and medicaments contain-  
Serial No.: 109/675,300 ) ing them  
Filed: September 30, 2003 ) Group Art Unit: 1626  
Examiner:

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Attached Form PTO/SB/08A lists references which may be considered to be material to the above-identified application by the Patent Examiner. Copies of these references are enclosed. Entry into the record is respectfully requested.

If any additional fee might be required in connection with this matter, please charge our Deposit Account No. 23-0785.

Respectfully submitted,

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER


By Martin L. Katz  
Martin L. Katz, Reg. No. 25,011

Date: June 11, 2004

Citicorp Center, Suite 3800  
500 West Madison Street  
Chicago, Illinois 60661-2511  
312/876-1800

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage for First Class Mail in an envelope addressed to: Mail Stop Patent Applications, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on **June 11, 2004.**

  
Rebecca J. Willis

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

3

Application Number

10/675,300

Filing Date

September 30, 2003

First Named Inventor

Wilfried Lubisch, et al.

Group Art Unit

1626

Examiner Name

Attorney Docket No.

ABB10010P0911US

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
		US- 5,594,023	January 14, 1997	Sanofi	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO 01/98295 A1	Dec. 27, 2001	Sanofi-Synthelabo		
		WO 01/55134 A2	Aug. 2, 2001	Sanofi-Synthelabo		
		WO 01/55130 A2	Aug. 2, 2001	Sanofi-Synthelabo		
		WO 01/64668 A2	Sep. 7, 2001	Sanofi-Synthelabo		
		WO 03/008407 A2	Jan. 30, 2003	Sanofi-Synthelabo		
		WO 98/25901	Jun. 18, 1998	Sanofi		
		WO 93/15051	Aug. 5, 1993	Elf Sanofi		
		WO 95/18105	Jul. 6, 1995	Sanofi		
Examiner Signature					Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. <sup>6</sup> Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

Application Number

10/675,300

Filing Date

September 30, 2003

First Named Inventor

Wilfried Lubisch, et al.

Group Art Unit

1626

Examiner Name

Attorney Docket No.

ABB10010P0911US

## **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BARBERIS, et al., Structural bases of vasopressin/osytocin receptor function, J. Endocrinology, 1998, 223-229, Vol. 156, France	
		HULME, et al., Quaternary Substitued PDE4 Inhibitors I: The Synthesis and In Vitro Evaluation of a Novel Series of Oxindoles, Bioorg. & Med. Chem. Lett, 1998, 175-178, Vol. 8, United Kingdom	
		WERSINGER, et al., Vasopressin V1b receptor knockout reduces aggressive behavior in male mice, Molecular Psychiatry, 2002, 975-984, Vol. 7, United Kingdom	
		GRIEBEL, et al, Anxiolytic- and antidepressant-like effects of the non-peptide vassopressin V <sub>1b</sub> receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders, PNAS, 2002, 6370-6375, Vol. 99, France	
		SERRADEIL-LE GAL, et al, J. Pharm. Exp. Ther., 2002, 1122-1130, Vol. 300, France	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.